NCT03916744 2023-03-10A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast CancerGenentech, Inc.Phase 1 Completed75 enrolled 24 charts